Chronological Timeline
|
| . 2007 Pharmatel Fresenius Kabi launches Voluven® into Australia, an innovative new product for volume therapy. 2006 Pharmatel Fresenius Kabi launches the Fresenius Kabi range of enteral nutrition and infusion technology devices onto the Australian market, and expands the range of parenteral nutrition products that are available. 2005 Pharmatel Fresenius Kabi launches Kabiven®, a 3-chamber all-in-one complete parenteral nutrition product is launched onto the Australian market Colazide®, a new treatment for ulcerative colitis, is first registered in Australia. 1 September 2004 Pharmatel Fresenius Kabi Pty Ltd is formed by a joint venture between Pharmatel Pty Ltd and Fresenius Kabi, allowing Pharmatel Fresenius Kabi to offer a greater range of nutrition products to the Australian and New Zealand markets. 2003 Pharmatel Opens a TGA licensed compounding site in Melbourne, enhancing the company's ability to service the market. 2000 Fresenius Kabi accelerated its worldwide business expansion by opening up new growth markets in Asia, Africa and Latin America as well as expanding the service program. 1999 Fresenius Kabi is formed by combining Fresenius Group's Pharma division with the infusion solution business acquired from Pharmacia & Upjohn (Kabi). The new company is Europe's leader in the field of nutrition and infusion therapy, offering a comprehensive product and service portfolio worldwide for hospitals and patients at home. Launch of a new generation of hydroxyethyl starch for volume therapy. 1997 Fresenius introduces the world’s first dipeptide solution for parenteral nutrition. Inauguration of the state-of-the-art infusions solutions plant (Friedberg, Hesse), the most modern one in Europe. 1991 Pharmatel commenced compounding Aseptic drugs for Australian hospitals, with a focus on Oncology products. 1985 Pharmatel founded by well known Australian pharmacist George Shortis. The Company quickly became a market leader in bowel preparation and developed a strong reputation for its high level of services. 1981 Fresenius in Europe establishes the home care concept, by which patients who have to be fed enterally (intake of nutrients involving the gastro-intestinal tract) can be cared for at home. 1980 Fresenius sets worldwide standards in volume therapy with the introduction of a new starch solution. 1974 Fresenius starts to manufacture infusion solutions and medical disposables. 1971/72 Fresenius introduce a novel amino acid solution achieving a decisive breakthrough in parenteral nutrition therapy. Development of an innovative volume replacement solution in the field of fluid therapy/blood substitution. 1966 Fresenius starts to sell dialysis machines and gains substantial market shares. 1912 The pharmacist and proprietor of the Hirsch Pharmacy, Dr. Eduard Fresenius, founds the pharmaceutical company Dr. E. Fresenius. Its main products are pharmaceutical specialities such as injection solutions, serologic reagents and Bormelin nasal ointment. 1462 The Hirsch Pharmacy is opened in Frankfurt, Germany. The Fresenius family assumes ownership in the 18th century. |
 | |